SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-030773
Filing Date
2024-03-05
Accepted
2024-03-05 08:17:38
Documents
16
Period of Report
2024-03-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm247868d1_8k.htm   iXBRL 8-K 23861
2 EXHIBIT 99.1 tm247868d1_ex99-1.htm EX-99.1 53466
6 GRAPHIC tm247868d1_img001.jpg GRAPHIC 2744
  Complete submission text file 0001104659-24-030773.txt   261271

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nvct-20240305.xsd EX-101.SCH 3015
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nvct-20240305_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nvct-20240305_pre.xml EX-101.PRE 22359
17 EXTRACTED XBRL INSTANCE DOCUMENT tm247868d1_8k_htm.xml XML 3583
Mailing Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024
Business Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024 360-837-7232
Nuvectis Pharma, Inc. (Filer) CIK: 0001875558 (see all company filings)

IRS No.: 862405608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41264 | Film No.: 24718376
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)